Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. Show more

890 Winter Street, Waltham, MA, 02451, United States

Biotechnology

Healthcare

Market Cap

468.2M

52 Wk Range

$5.14 - $33.68

Previous Close

$8.66

Open

$8.44

Volume

734,937

Day Range

$8.23 - $8.63

Enterprise Value

97.24M

Cash

372.4M

Avg Qtr Burn

-22.24M

Insider Ownership

14.94%

Institutional Own.

95.39%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Verekitug Details Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Verekitug Details Severe asthma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Verekitug Details Chronic Obstructive Pulmonary Disease (COPD)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.